ArticleFrontiers in oncology2022
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Overall Survival with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Fully automated volumetric assessment of tumor burden using artificial intelligence onEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer.Nuclear medicine and molecular imaging · 2025Review
- PSMA-based theranostics in diagnosing and treating prostate cancer in the Asian male population: a narrative review.Frontiers in oncology · 2025Review
- Review
- From Despair to Hope: First Arabic Experience ofCancers · 2024Article
- Current clinical application of lutetium‑177 in solid tumors (Review).Experimental and therapeutic medicine · 2024Review
- Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.Chemical & biomedical imaging · 2024Review
- The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [Breast cancer research : BCR · 2024Article
- Theranostics - a sure cure for cancer after 100 years?Theranostics · 2024Review
- Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study.Therapeutic advances in medical oncology · 2024Article
- Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Improved quality control of [EJNMMI radiopharmacy and chemistry · 2023Article
- Deep learning based on 68Ga-PSMA-11 PET/CT for predicting pathological upgrading in patients with prostate cancer.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: There is increasing evidence for convincing efficacy and safety of Methods: Forty consecutive patients with mCRPC were enrolled from December 2019 to September 2021. Eligible patients received Results: All patients underwent a total of 86 cycles of Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.